Gilead Sciences· @GileadSciences · X·· 2026-06-26精选AI 评分73
AI 导读
吉利德宣布其治疗一线转移性三阴性乳腺癌（mTNBC）的疗法获得 FDA 批准。公司称此次获批体现其在肿瘤治疗领域的创新投入，并附上相关报道链接。
推荐理由
吉利德宣布其疗法获 FDA 批准用于一线转移性三阴性乳腺癌，读者可据此了解该适应症的监管进展。
正文
#InTheNews: Yesterday, we received FDA approval for our treatment for first-line metastatic triple-negative breast cancer (mTNBC). Read recent coverage highlighting the impact of this approval and our commitment to driving innovation in cancer care: https://gilead.inc/4aliqp2
来源：Gilead Sciences · x.com